DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
A••••••• O••••• T••••••• I••
Pharmaceuticals, Biotechnology & Life Sciencesgroup grade Aon a schedule nowsponsor unattributed
Principal held
at least $19.5M
sum of BDC pieces, a lower bound
Fair value
$19.4M
106c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Feb 15, 2029
no dated debt inside 24 months
On the tape since
Jun 30, 2026
latest Jun 30, 2026
Events
1
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $19.5M | 106c | SOFR+775 bp | Feb 15, 2029 | 1 |
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| R••••• G••••• F•••••• C•••• | term loan first lien Investment T••• S••••• S•••••• I••••••• R••• S•••+7.75%, 10.90% floor, 5.60% ETP A•••••••• | $19.5M | $19.4M 106c | SOFR+775 bp |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $19.5M | $19.4M | 106c | 0 |
What changed
- New borrower on a BDC scheduleJun 30, 2026
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- A••••••• O••••• T••••••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Pharmaceuticals, Biotechnology & Life Sciencesreportedas one filer wrote it